BCL2L11 and leukemia: Moreover, oridonin diminishes the expression of miR-17 and miR-20a and triggers cell death in both doxorubicin-sensitive and -resistant leukemia cells via derepressing BCL2L11, a target mRNA of miR-17 and miR-20a [80] (Figure 3 and Table 3).